July 2017

Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma

July 17, 2017

Evidence-Based Oncology

Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.

Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma

July 17, 2017

Evidence-Based Oncology

A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients

July 17, 2017

Evidence-Based Oncology

Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC

July 17, 2017

Evidence-Based Oncology

In a discussion on state-of-the-art uses for immunotherapy in the management of non—small cell lung cancer (NSCLC) at the American Society of Clinical Oncology Annual Meeting, oncologists shared their experiences with managing toxicities from immunotherapy and discussed the role of immunotherapy in specific patient populations.

An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC

July 17, 2017

Evidence-Based Oncology

An early stage international clinical trial is actively enrolling patients with relapsed, advanced or metastatic non—small cell lung cancer (NSCLC) to evaluate response to a combination of atezolizumab and daratumumab, according to a study at the 2017 Annual Meeting of the American Society of Clinical Oncology that detailed the trial design.

LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer

July 18, 2017

Evidence-Based Oncology

A study presented by researchers from Massachusetts General Hospital (MGH), which queried the effect of thoracic radiotherapy and immune checkpoint inhibition on the risk of pneumonitis or immune-related adverse events (irAEs), found that radiotherapy did not increase patient risk for pneumonitis and that elevated expression of lactate dehydrogenase (LDH) could be a predictor of grade 2 or higher irAEs.

Alectinib May Be a New Standard of Care for Treatment-Naïve ALK-Positive NSCLC

July 18, 2017

Evidence-Based Oncology

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting showed that alectinib demonstrates efficacy and favorable tolerability compared with crizotinib in the primary results of the global phase 3 ALEX study in patients with treatment-naïve advanced anaplastic lymphoma kinase (ALK)-positive non—small cell lung cancer (NSCLC).

Dacomitinib a New First-Line Option for Advanced EGFR Mutation—Positive NSCLC

July 18, 2017

Evidence-Based Oncology

ARCHER 1050, the first phase 3 head-to-head study of epithelial growth factor receptor (EGFR) tyrosine kinase inhibition, has produced results that demonstrate statistically significant and clinically meaningful improvement with dacomitinib compared with gefitinib (Iressa) as first-line therapy for non—small cell lung cancer (NSCLC) with EGFR-activating mutations.

Androgen Deprivation, With or Without Radiotherapy, New Standard of Care in High-Risk Prostate Cancer

July 18, 2017

Evidence-Based Oncology

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting reported a significant effect on overall and failure-free survival from the addition of abiraterone at the start of androgen deprivation therapy in men with high-risk prostate cancer.

Trabectedin and Lurbinectedin Effective in BRCA2-Associated Metastatic Breast Cancer

July 18, 2017

Evidence-Based Oncology

An interim analysis of two phase 2 trials, reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting, has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer.

HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults

July 19, 2017

Evidence-Based Oncology

The incidence of human papilloma virus (HPV)-positive oropharyngeal cancer can be reduced with a prophylactic vaccine, according to a collaborative study that was presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.

Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO

July 19, 2017

Evidence-Based Oncology

Results from a collaborative study across the United States indicate that patients with colon cancer who had a healthy body weight, engaged in physical activity, and ate a healthy diet had longer survival.

Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer

July 19, 2017

Evidence-Based Oncology

The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.

Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma

July 19, 2017

Evidence-Based Oncology

In a study performed by the Grupo Español de Investigación en Sarcomas, Fas biomarker detection showed value in predicting progression-free and overall survival after trabectedin administration to patients with advanced soft tissue sarcoma.

Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma

July 19, 2017

Evidence-Based Oncology

In a late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting, researchers presented an interim analysis of a randomized phase 2 trial of second- or third-line nivolumab, with or without ipilimumab, in patients with second- or third-line malignant pleural mesothelioma.

Ibrutinib vs No Consolidation Are Being Compared Following Autologous HSCT in IRONCLAD Trial

July 20, 2017

Evidence-Based Oncology

A poster session at the 2017 American Society of Clinical Oncology Annual Meeting presented the trial details of IRONCLAD, a randomized phase 3 study of ibrutinib versus no consolidation following autologous hematopoietic stem cell transplantation for activated-B-cell subtype relapsed diffuse large B-cell lymphoma.

Web-Based Patient Reporting of Symptoms Shown to Improve Survival in Patients With Metastatic Solid Tumors

July 20, 2017

Evidence-Based Oncology

According to outcome results presented at a plenary session at the 2017 American Society of Clinical Oncology Annual Meeting, patients receiving routine outpatient chemotherapy for metastatic solid tumors who self-reported 12 common symptoms via tablet computers experienced an overall survival benefit over those who received usual care.

Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data

July 20, 2017

Evidence-Based Oncology

A kickoff session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago turned in to a lively discussion on ensuring that the data used to inform patient care and create healthcare policies hold value, which could entail foraging real-world data captured in health records.

Do We Have Adequate Surveillance in Cancer Care?

July 20, 2017

Evidence-Based Oncology

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology led by Katherine Van Loon, MD, MPH, examined retrospective surveillance data in 3 cancers: non—small cell lung cancer, head and neck cancer, and colorectal cancer.

ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation

July 21, 2017

Evidence-Based Oncology

The diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA), according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

July 21, 2017

Evidence-Based Oncology

After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.

Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3

July 21, 2017

Evidence-Based Oncology

Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.

CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference

July 21, 2017

Evidence-Based Oncology

CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?

July 21, 2017

Evidence-Based Oncology

A discussion at the 2017 American Society of Clinical Oncology Annual Meeting addressed practical solutions to address the financial toxicity of cancer care and identified leads for future intervention studies aimed to prevent or reduce this burden.

Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery

July 22, 2017

Evidence-Based Oncology

Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Brazilian Study Queries: Is NGS Cost-Effective in Advanced Lung Cancer?

July 22, 2017

Evidence-Based Oncology

In a study presented at the 2017 American Society of Clinical Oncology Annual Metting, researchers from the Brazilian Cancer Foundation and the Brazilian National Cancer Institute evaluated the cost-effectiveness of a unique exam using next-generation sequencing versus other routine tests.

SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors

July 22, 2017

Evidence-Based Oncology

In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine tumors to analyze their resource utilization.